



Supplementary Table 1. Relationships between mRS at symptom onset or after first-line immunotherapy and patient outcome within each treatment group.

	Complete recovery (mRS = 0)	Incomplete recovery (mRS ≥ 1)	χ^2	<i>p</i> value
Second-line immunotherapy group			1.394	<i>p</i> = 0.238
mRS at symptom onset				
mRS ≤ 3	10	4		
mRS ≥ 4	23	20		
mRS after first-line immunotherapy			4.059	<i>p</i> = 0.044
mRS ≤ 3	17	6		
mRS ≥ 4	16	18		
Repetitive first-line immunotherapy group				
mRS at symptom onset			0.215	<i>p</i> = 0.643
mRS ≤ 3	8	6		
mRS ≥ 4	21	21		
mRS after first-line immunotherapy			1.125	<i>p</i> = 0.289
mRS ≤ 3	17	12		
mRS ≥ 4	12	15		
Oral prednisolone group			0.561	<i>p</i> = 0.756
mRS at symptom onset				
mRS ≤ 2	43	9		
mRS = 3	74	18		
mRS ≥ 4	73	21		
mRS after first-line immunotherapy			13.006	<i>p</i> = 0.001
mRS ≤ 2	115	24		
mRS = 3	52	8		
mRS ≥ 4	23	16		

Follow-up days w/ deceased patients



Follow-up days w/o deceased patients



Supplementary Figure 1. Violin plot of distribution of follow-up duration of patients.